05:31 PM EDT, 03/24/2025 (MT Newswires) -- Actinium Pharmaceuticals ( ATNM ) said Monday it signed a supply agreement with Eckert & Ziegler for Actinium-225.

Financial details weren't disclosed.

Under the agreement, Actinium Pharmaceuticals ( ATNM ) will access Eckert & Ziegler's high-quality Actinium-225 to advance Actimab-A and other development candidates for US and international clinical trials.

Ac-225 targeted radiotherapy offers precise cancer treatment by delivering high-energy alpha particles with minimal penetration. Actimab-A is an Ac-225-based therapy that specifically targets CD33, a receptor overexpressed in acute myeloid leukemia and other myeloid disorders, the company said.